BusinessDermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from TakedaBy Nasdaq OMXSep 12, 2016, 11:30 AM UTC
BusinessDermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of DermatologyBy Nasdaq OMXMar 14, 2016, 11:30 AM UTC
BusinessDermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 3, 2016, 12:30 PM UTC
BusinessDermira to Report Fourth Quarter and Full Year 2015 Financial ResultsBy Nasdaq OMXMar 1, 2016, 9:05 PM UTC
BusinessDermira to Present at Cowen and Company 36th Annual Health Care ConferenceBy Nasdaq OMXMar 1, 2016, 12:30 PM UTC
BusinessDermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary HyperhidrosisBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
BusinessDermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline DataBy Nasdaq OMXJan 8, 2016, 6:00 AM UTC
